Publication | Open Access

Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial

Hematological MalignancyInterim AnalysisOncologyMarrow TransplantationTransplantationStem Cell TransplantationImmunologyHematologyMultiple MyelomaImmunotherapyMedicineCell TransplantationAutologous Stem-cell Transplantation